AngioDynamics Q2 pro forma sales up 9.2% to $73.0M; raises FY25 EBITDA guidance to $1-3M

ANGIODYNAMICS INC

2025-Q2 EPS reported -$0.58 vs consensus -$0.12 ▼ miss (-373.9%)

Pro forma net sales $73.0M (+9.2% YoY); Med Tech $31.5M (+25%) led by AngioVac (+50.7%), Auryon (+21.8%), AlphaVac (+33.3%), NanoKnife disposables (+23.1%).
GAAP net loss $10.7M ($0.26 loss/share); adjusted loss $0.04/share vs $0.08 loss prior year.
Adjusted EBITDA $3.1M (vs $0.0M); FY25 guidance raised to $1-3M from loss of $2.5M-$0; adjusted loss per share guidance improved to $0.34-0.38.
Received FDA 510(k) clearance for NanoKnife prostate tissue ablation and CPT Category I codes for IRE (effective Jan 2026).
Cash $54.1M; operating cash flow $2.5M; $1.1M used on share repurchases in Q2.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.